Extracellular HMGB1 interacts with Toll-like receptors (TLRs) and receptor for advanced glycation end products (RAGE) on the DCs, which are involved selectively in the cross-priming of anti-tumor T lymphocytes in vivo [27, 28]. This evidence concerns the gene HMGB1 and neoplasm.